Azelis announced a new agreement with Roquette for the distribution of their pharmaceutical cellulose product range in India.  This collaboration expands Azelis India’s footprint in the pharmaceutical excipient market segment.

This new mandate builds upon and strengthens Azelis and Roquette’s global strategic partnership which spans multiple regions and industries.

This agreement is consistent with Azelis’ commitment to grow organically with strategic partners and expand its presence in developing and emerging economies such as India.

Through this collaboration, Azelis India is expanding its comprehensive product portfolio with the inclusion of Roquette’s Microcrystalline Cellulose (MCC) and Croscarmellose Sodium (CCS) products. The new agreement is effective immediately.

“Azelis has been our preferred partner for many years, and we are happy to continue this pharma relationship in India, expanding from the Middle East & Africa. We are confident in Azelis’ ability to deliver best-in-class services and solutions to our customers, who will now have access to a wider range of customizable solutions for various applications. The synergies arising from combining our ingredients with Azelis’ technical capabilities will lead to more opportunities and growth in the region,” Oscar Manuel Cortes Gutierrez, Roquette Global Head of Pharma Distribution Management, said.

Aparna Khurana, Azelis India Managing Director, states: “The addition of Roquette’s innovative and plant-based ingredients to our pharma product offering in India can only be to our customers’ benefit. By strengthening our lateral value chain, we will be able to offer a more complete and complementary pharma portfolio, becoming a one-stop-shop for customers to formulate solutions that meet consumers’ unique requirements. We will work to ensure the continued success of our collaboration, by leveraging our sales capabilities and market knowledge.”